Abstract. Sprouty2 (Spry2) was identified recently as a tumor suppressor gene in cancer cells which inhibits the activation of receptor tyrosine kinases (RTKs). The present study explored the effect of Spry2 in colon cancer cells in order to assess its potential use in the treatment of colon cancer. Expression of Spry2 inhibited the growth of a colon cancer cell line, HCT116, and induced sensitization to fluorouracil (5-FU) and metformin. Spry2 promoted apoptosis of cancer cells in association with activation of the phosphatase and tensin homolog deleted on chromosome 10 (PTEN) pathway and the blockade of Ras-Raf-Erk signaling. Treatment of Spry2-HCT116 cells with metformin resulted in a more prominent effect on the inhibition of cell migration. Inhibition of microRNA-21 (mir-21) induced upregulation of Spry2 and PTEN which underscores the importance of mir-21 in Spry2-associated tumorigenesis of the colon. These results point toward a potential strategy for colon cancer treatment worthy of further investigation.
Introduction
Growth factor signaling by receptor tyrosine kinases (RTKs) regulates several important cellular functions in tumor cells, such as proliferation and invasion. A negative feedback mechanism is one of the mechanisms that provide effective control via modulation of the activated RTKs pathway. Sprouty (Spry) was originally described in Drosophila as an antagonist to Breathless, the insect equivalent of fibroblast growth factor (FGF) receptor, since the loss of function of Spry led to overactive FGF signaling, hence, an excessive branching network, while forced expression of Spry blocked tracheal branching (1) . Subsequent studies have demonstrated that Spry can also inhibit the Drosophila epithelial growth factor receptor (EGFR), as well as other RTKs (2) (3) (4) .
Mammals have at least four isoforms of Spry protein (Spry1-4). All Spry genes have a highly conserved C-terminal cysteine-rich domain that is important for the membrane localization of Spry family members (5, 6) . The N-terminal domain of Spry family members is less well conserved (25-37%) and may impart unique functions to individual family members. The N-terminal domain of Spry2 binds to c-Cbl, a ring-finger domain containing protein, and one involved in targeting the EGF receptor (7) (8) (9) (10) . Within the Spry family, Spry2 exhibits the highest level of homology to the ancestral gene. Regarding cellular functions, Spry2 owes its ability to its inhibition of Akt and Erk activation induced by some, but not all RTKs (11) . Previous reports have shown that Spry2 was de-regulated in human cancer, including breast, prostate and liver cancer (12) (13) (14) . Overexpression of Spry2 in osteosarcoma cancer cells inhibits proliferation and migration, implying a novel strategy in cancer treatment (15) .
The first identified biochemical hallmark of tumor cells was a shift in glucose metabolism from oxidative phosphorylaMicroRNA-21-mediated regulation of Sprouty2 protein expression enhances the cytotoxic effect of 5-fluorouracil and metformin in colon cancer cells YIN-HSUN FENG  1-3 , CHAO-LIANG WU   2,4 , AI-LI SHIAU 2, 5 , JENQ-CHANG LEE 6 , JAN-GOWTH CHANG 7 , PEI-JUNG LU 2 tion to aerobic glycolysis. In the 1920s, Warburg proposed a defect in the cellular energy of tumor cells, utilizing glycolysis instead of mitochondrial oxidative phosphorylation for glucose metabolism, even in oxygen-rich conditions (the 'Warburg effect') (16) . The adenosine monophosphate (AMP)-activated protein kinase (AMPK), a master metabolic regulator, has been connected to several human tumor suppressors. It is highly conserved as a heterotrimer, and composed of an α catalytic kinase subunit and β and γ regulatory subunits. AMPK is activated under conditions of decreased intracellular ATP and increased intracellular AMP, such as nutrient deprivation or hypoxia. While activated, AMPK increases catabolic ATP-generating processes such as fatty-acid oxidation and inhibits ATP-consuming biosynthetic processes such as protein, cholesterol and fatty-acid synthesis (17) . In mammalian systems, the dominant upstream kinase responsible for activating AMPK is a novel kinase named LKB1, which had been previously identified as the tumor suppressor mutated in the rare autosomal dominant Peutz-Jeghers syndrome (18) . Patients with Peutz-Jeghers syndrome universally develop gastrointestinal polyps and are predisposed to several types of cancer, especially colon cancer at an early age. Genetic depletion of LKB1 in mouse embryonic fibroblasts (MEFs) results in a loss of AMPK activation following energy stresses that raise AMP (19) . Metformin, a biguanide commonly used in the treatment of type 2 diabetes mellitus, recently demonstrated the ability to inhibit the breast cancer cell growth through activation of AMPK and inactivation of a mammalian target of rapamycin (mTOR) and S6 kinase (20, 21) . In p53 (-/-) colon cancer cells, metformin was found to increase cell apoptosis, but to activate autophagy in p53 (+/+) cells (22) . Another report showed that 5-aminoimidazole-4-carboxamide ribonucleoside (AICAR), a pharmacologic activator of AMPK, enhanced apoptosis of wild-type p53 colon cancer cells co-treated with tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL) (23) . It is critical to explore the therapeutic strategy of metformin and its link with other treatment options in colon cancer.
Materials and methods
Cell culture. The human colon cancer cell line, HCT116, was obtained from the American Type Culture Collection and cultured in Dulbecco's modified Eagle's medium/F12 with 10% fetal bovine serum.
Reagents. Fluorouracil (5-FU) and methylthiazolydiphenyltetrazolium bromide (MTT) powder were purchased from Sigma-Aldrich (USA). Metformin was obtained from Alexis (Germany) and was dissolved in water. Anti-phosphorylated-AMPK, anti-phosphorylated Akt, and anti-total Akt were from Cell Signaling (USA). Anti-PTEN was obtained from Santa Cruz Biotechnology, Inc., and anti-α-tubulin was purchased from Sigma-Aldrich. Horseradish peroxidase-conjugated antirabbit IgG and anti-mouse IgG were from Pierce (USA). the Annexin V kit and the enhanced chemiluminescencent (ECL) were from Roche Diagnostic (USA). Anti-poly (ADP-ribose) polymerase (PARP) was from BD Pharmingen (USA) and anti-BCL2 was from Transduction Laboratories (USA). AntiSpry2 was obtained from Upstate Biotechnology (USA). Cytotoxicity assay. The cytotoxity of cells was assessed by the MTT assay. In brief, HCT116 colon cancer cells were transfected with Spry2-GFP plasmid or vector only plasmid, using the Lipofectamine method. Forty-eight hours after transfection, Spry2-HCT116 and vector-HCT116 were cultured in a 96-well plate (Corning, Inc., USA) at a density of 4,000 cells/ well in DMEM/F12 with 10% FBS (controlled medium). After 24 h incubation, 25 µM of 5-FU or 20 mM of metformin was added to DMEM/F12 with 10% FBS, in a total volume of 200 µl/well, to replace the original DMEM/F12. After 96 h, 20 µl of 5 mg/ml MTT solution was added to each well. Plates were incubated in the dark for 2 h and then the crystal was eluted with 100 µl DMSO after removal of the culture medium and the MTT solution. The absorbance was measured at 570 nm using a microtiter plate reader (MRX Revelation, Dynex, USA). and Mg 2+ -free PBS and harvested after incubation with 2 mM EDTA in PBS for 10 min. Floating and attached cells were pooled and rinsed twice with PBS. Cells were resuspended in 1X binding buffer (Axxora Platform, USA) and incubated with FITC-conjugated Annexin V for 15 min at room temperature in the dark, using the FITC-Annexin V apoptosis detection kit (Roche Diagnostic). Cells were washed twice with 1X binding buffer. The samples were immediately analyzed on FACSCalibur flow cytometer (Becton-Dickinson Immunocytometry System, USA) using the CellQuest Pro Software and the WinMDI 2.9 software. Propidium iodide was added right before the analysis of these samples.
Protein extraction and western blot analysis. HCT116 cells were transfected with Spry2-GFP plasmid or vector-only plasmid (control), using Lipofectamine. Twenty-four hours after transfection, cells were treated with either controlled medium (DMEM/F12 with 10% FBS), controlled medium with 25 µM of 5-FU, or controlled medium with 5 mM of metformin, for 48 h. Cells were washed twice with PBS and lysed in 300 µl lysis buffer (20 mM Tris-HCl, pH 8.0, 100 mM NaCl, 1 mM EDTA, 0.5% nonidet P40, 0.5% Triton X-100, 1 mM phenylmethylsulfonyl fluoride, 1 mM NaF, 1 mM sodium orthoyanadate, 1 mg each of aprotinin, leupeptin, and pepstatin/ml) and were processed as described previously (24) . Separation of protein was performed on 10% polyacrylamide gels with 5% polyacrylamide stacking gel. After electrophoretic transfer (Amersham Pharmacia Biotech, USA) of protein from the SDS polyacrylamide gel to polyvinylidene difluoride membranes (Millipore, USA), the membranes were blocked with buffer containing 20 mM Tris-HCl, pH 7.5, 150 mM NaCl, 0.05% Tween-20, 5% Blotto (Bio-Rad, USA) at 4˚C overnight and probed with antibodies of interest. Horseradish peroxidase-conjugated anti-rabbit IgG and anti-mouse IgG were used as secondary antibodies. The position of the protein was visualized using the ECL reagent.
Cell migration/wound-healing assay. For the wound-healing assay, 48 h after transfection with Spry2-GFP or vector-only plasmid using Lipofectamine, transfected cells were plated separately overnight to achieve a confluent cell layer in a 12-well plate. Then, the medium was replaced with DMEM/F12 and 10% FBS (controlled medium) with or without metformin in the concentration of 20 mM. After making a scratch on the cell layer with a needle tip, wound-healing was visualized by monitoring the migrating cells in the gap during a 24-h postscratch period.
Inhibition of microRNA-21 expression. The endogenous microRNA-21 (mir-21) was suppressed by transfection of the mir-21 inhibitor (Qiagen, Germany) in colon cancer cells. According to the manufacturer's protocol, 10.3 µl mir-21 inhibitor (20 µM stock) was diluted in 100 µl culture medium without serum. Twenty microliters HiPerFect Transfection Reagent (Qiagen) was added to the diluted mir-21 inhibitor. The samples were incubated for 10 min at room temperature (15-25˚C) to allow the formation of transfection complexes. The complexes were added drop-wise onto the cells. The cells were incubated with the transfection complexes under their normal growth conditions. Statistical analysis. Significance was assessed by a two-tailed Student's t-test. All data represent the average of a least three independent experiments. (Fig. 1B) .
Results

Spry2 enhances the cytotoxic effect of metformin and 5-FU
Spry2 enhances the cytotoxic effect of 5-FU or metformin through suppression of Akt and Erk activation followed by induction of cell apoptosis.
We utilized flow cytometry and western blot analysis to determine the regulatory mechanism of Spry2 in promoting cancer cell death. After treatment with 5-FU, metformin, or a controlled medium for 48 h, the Annexin V stain of Spry2-and vector-HCT116 cells was measured by flow cytometry (Fig. 2A) . (Fig. 2B) .
Using western blot analysis to demonstrate protein regulation, metformin induced PARP cleavage and decreased BCL-2 expression, leading to cell apoptosis, which corresponds to the net result of activation of AMPK and inactivation of Akt. Spry2 protein has been known to inhibit cell growth by inhibiting activation of the Ras/Raf/Erk pathway as a negative regulator. This study has demonstrated that Spry2 can also suppress the activation of the Akt pathway by inducing expression of PTEN, an important tumor suppressor (Fig. 3) . These results confirmed that Spry2 can enhance the originally suppressive effect of either 5-FU or metformin in colon cancer cells.
Spry2 enhances the migration inhibition of metformin in colon cancer cells.
It is known that Spry2 can inhibit tumor proliferation and migration, but there is limited information about whether treatment with metformin in Spry2 overexpressed cancer cells generates better inhibition on cell migration, so we used a wound-healing assay to test this hypothesis. The migration distance was measured by a timelapse microscope camera within 24 h. The results showed that expression of Spry2 can inhibit migration of HCT116 cells in a controlled medium (Spry2-HCT116, 15.462±1.469 µm/h; vector-HCT116, 21.691±2.475 µm/h, P<0.05). The suppressive effect of Spry2 in cell migration of HCT116 was also demonstrated in a controlled medium with 20 mM of metformin (Spry2-HCT116+metformin, 11.170±1.587 µm/h; vector-HCT116+metformin, 15.811±1.998 µm/h, P<0.05) (Fig. 4) . This implies that both strategies can work together to achieve better results in the control of tumor growth and migration. 
Suppression of mir-21 leads to increased expression of Spry2
and PTEN in accordance with a reduced proliferation of colon cancer cells. Our previous study had shown that expression of Spry2 is reversely correlated with expression of mir-21 in tumor samples of colon cancer patients (25) . It is still unclear that mir-21 has any influence on the Spry2 induced proliferation of colon cancer cells. In colon cancer cells, HCT116, mir-21 knockdown was associated with increasing expression of Spry2 and PTEN by western blot analysis (Fig. 5A) . The proliferation rate of colon cancer cells was reduced after the inhibition of mir-21 (Fig. 5B) . These results correlated with the oncogenic effect of mir-21 in colon cancer as previously reported (26-28).
Discussion
There is emerging evidence indicating that Spry2 protein is downregulated in cancer cells and that the ectopic expression of Spry2 can inhibit cancer cell growth (12, 13, 15) . Spry2 tumor suppression is possibly induced through inactivation of the Erk and Akt pathways. Resistance to primary therapy with drugs or medication is a problem requiring urgent attention in cancer treatment. More and more studies are focusing on conquering this tough problem through multi-pathway inhibition. Spry2 is a possible candidate for this strategy since it is a novel target which can suppress many RTKs, including fibroblast growth factor receptor and vascular epithelial growth factor receptor, and it also directly suppresses downstream effectors of RTKs, such as Ras, Raf and Erk. Spry2 protein may act as a competitive inhibitor of Erk signaling through at least two potential mechanisms. The COOH terminus of Spry2 can bind to RAF1, inhibiting kinase activity (29) . Furthermore, Spry2 protein uncouples receptor tyrosine kinase signaling from the activation of Ras, possibly by sequestration of GRB2, an adaptor protein required for Ras activation (30, 31) . For the Akt pathway, PTEN is activated by Spry2, which leads to inactivation of Akt signaling. The downregulation of Spry2 in cancer cells may confer a proliferative advantage to tumor cells by allowing unchecked activation of the Ras/Erk pathway, which would normally be controlled by relatively higher expression levels of Spry2 in normal tissue. Several mechanisms may account for the reduced Spry2 expression in cancer cells and the association with carcinogenesis. Accordingly, in cells lines derived from non-small cell lung carcinoma, metastatic lung cancer cells tend to have a lower expression of Spry2. In addition, an inverse correlation between Spry expression and tumor grade was observed in prostate cancer (13) . Actually, Spry2 has a potential antitumor property, but so far no data have shown that Spry2 can enhance other cancer treatment strategies. Our results showed that Spry2 was able to promote apoptosis in colon cancer cells and enhance the cytotoxic effect of the chemotherapeutic agent, 5-FU. 5-FU is the time-tested agent for systemic chemotherapy for colon cancer; however, the objective response rate to 5-FU is 15-20%. The therapeutic effect of 5-FU can be enhanced by combining 5-FU and other agents, such as leucovorin, oxaliplatin and irinotecan. Activation of growth factor receptor in colon cancer has been given greater attention, and specific treatment for epidermal growth factor receptor and vascular growth factor has been deployed to manage patients with metastatic colon cancer. The Spry2 mediated enhancement of the cytotoxic benefit of the 5-FU regimen implies that Spry2 may be a surrogate marker for prediction of tumor response and may play an important role in resistance to chemotherapy.
Spry2 also has the ability to generate a better effect with metformin, an AMPK activator. AMPK is known as a master negative regulator in the protein synthesis of various cells, and it has been considered as a novel therapeutic target for the treatment of cancer and other metabolic diseases (32) . Recent studies on the effects of metformin on the cell signaling network have extended from the context of diabetes research to the regulation of cancer cells. The cell proliferative effects of activated AMPK via the Akt/mammalian target of rapamycin (m-TOR) or phosphatidylinositol 3-kinase (PI3K) signaling were shown in endothelial cells. In breast cancer cells, the inactivation of LKB1 by reactive lipid species was shown to inhibit the phosphorylation of AMPK, as well as the downstream Tuberous sclerosis protein (TSC)-mTOR-S6K cascade (33) . Here we demonstrated metformin alone can inhibit the proliferation and migration of colon cancer cells. Cell apoptosis, demonstrated by Annexin V assay, was not increased after metformin treatment, which can be partially explained by autophagocytosis. However, the combination of Spry2-active cancer cells and metformin treatment resulted in the additional benefit of cell killing. These data support the current concept of inactivation of oncogenic pathways and suggest a the central role of Spry2 in cancer treatment (Fig. 6) . 
